Halozyme Therapeutics (NASDAQ:HALO) Hits New 12-Month High at $29.12

Halozyme Therapeutics, Inc. (NASDAQ:HALO)’s stock price hit a new 52-week high during mid-day trading on Monday . The stock traded as high as $29.12 and last traded at $29.00, with a volume of 50692 shares traded. The stock had previously closed at $28.51.

HALO has been the subject of a number of recent analyst reports. JMP Securities increased their price target on Halozyme Therapeutics from $24.00 to $34.00 and gave the stock an “outperform” rating in a report on Tuesday, May 12th. Benchmark initiated coverage on Halozyme Therapeutics in a report on Wednesday, July 1st. They set a “buy” rating and a $39.00 price target for the company. BidaskClub upgraded Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday, July 2nd. Piper Sandler increased their price target on Halozyme Therapeutics from $28.00 to $31.00 and gave the stock an “overweight” rating in a report on Thursday, July 2nd. Finally, BMO Capital Markets increased their price target on Halozyme Therapeutics from $27.00 to $35.00 and gave the stock an “outperform” rating in a report on Tuesday, May 12th. Three research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $28.73.

The company has a debt-to-equity ratio of 6.66, a current ratio of 11.14 and a quick ratio of 10.15. The company has a 50 day moving average price of $24.62 and a 200 day moving average price of $20.78.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings results on Monday, May 11th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.02). The company had revenue of $25.30 million for the quarter, compared to analyst estimates of $42.96 million. Halozyme Therapeutics had a negative net margin of 48.75% and a negative return on equity of 48.92%. Halozyme Therapeutics’s revenue for the quarter was down 55.5% on a year-over-year basis. During the same quarter last year, the firm posted $0.01 EPS. Analysts anticipate that Halozyme Therapeutics, Inc. will post 0.75 earnings per share for the current year.

In related news, SVP Michael J. Labarre sold 21,387 shares of Halozyme Therapeutics stock in a transaction that occurred on Wednesday, May 20th. The shares were sold at an average price of $23.80, for a total value of $509,010.60. Following the sale, the senior vice president now owns 197,574 shares of the company’s stock, valued at approximately $4,702,261.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 2.60% of the stock is owned by company insiders.

Institutional investors have recently added to or reduced their stakes in the stock. Chevy Chase Trust Holdings Inc. purchased a new position in Halozyme Therapeutics in the 4th quarter valued at approximately $27,000. Quadrant Capital Group LLC purchased a new position in Halozyme Therapeutics in the 4th quarter valued at approximately $35,000. Point72 Hong Kong Ltd purchased a new position in shares of Halozyme Therapeutics during the 4th quarter valued at $56,000. Oppenheimer Asset Management Inc. purchased a new position in shares of Halozyme Therapeutics during the 1st quarter valued at $61,000. Finally, Partner Investment Management L.P. purchased a new position in shares of Halozyme Therapeutics during the 4th quarter valued at $82,000. Institutional investors and hedge funds own 95.37% of the company’s stock.

Halozyme Therapeutics Company Profile (NASDAQ:HALO)

Halozyme Therapeutics, Inc, a biotechnology company, engages in researching, developing, and commercializing novel oncology therapies in the United States, Switzerland, and internationally. Its human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit.

Featured Article: How can investors find ex-dividend dates?

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.